Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Page 1
Short and long-term metabolic outcomes in patients with type 1 and type 2 diabetes receiving a simultaneous pancreas kidney allograft.
Hau HM, Jahn N, Brunotte M, Lederer AA, Sucher E, Rasche FM, Seehofer D, Sucher R. Hau HM, et al. Among authors: rasche fm. BMC Endocr Disord. 2020 Feb 27;20(1):30. doi: 10.1186/s12902-020-0506-9. BMC Endocr Disord. 2020. PMID: 32106853 Free PMC article.
METHODS: Medical data (2001-2013) from all consecutive T1DM and T2DM patients who received a SPK or kidney transplant alone (KTA) at the University Hospital of Leipzig were analyzed. Donor, recipients and long-term endocrine, metabolic and graft outcomes were investigated …
METHODS: Medical data (2001-2013) from all consecutive T1DM and T2DM patients who received a SPK or kidney transplant alone (KTA) at the Uni …
Endemic influences of political regimes, healthcare systems, and preferences on the frequencies and incidences of nephropathies in eastern Saxony, Germany
.
Sedaghat S, Heshmati ES, Frese T, Rasche WG, Barinka F, Fahr F, Beige J, Schiekofer S, Rasche FM. Sedaghat S, et al. Among authors: rasche fm. Clin Nephrol. 2017 Dec;88(12):317-327. doi: 10.5414/CN109229. Clin Nephrol. 2017. PMID: 29115212
INTRODUCTION: The possible confounding influence of investigator-related preferences, available histological techniques, and healthcare systems on the frequencies and incidences of primary and secondary nephropathies was evaluated in this long-term observation. MATERIALS A …
INTRODUCTION: The possible confounding influence of investigator-related preferences, available histological techniques, and healthcare syst …
Influence of Erythropoiesis-Stimulating Agents on HbA1c and Fructosamine in Patients with Haemodialysis.
Rasche FM, Ebert T, Beckmann J, Busch V, Barinka F, Rasche WG, Lindner TH, Schneider JG, Schiekofer S. Rasche FM, et al. Exp Clin Endocrinol Diabetes. 2017 Jun;125(6):384-391. doi: 10.1055/s-0042-124577. Epub 2017 Apr 13. Exp Clin Endocrinol Diabetes. 2017. PMID: 28407666 Clinical Trial.
HbA1c is the most accepted laboratory parameter for the long term observation of glucose control. There is still much of a debate about the use of HbA1c as a metabolic indicator in diabetic patients (DM) on haemodialysis (HD) and erythropoiesis-stimulating agent (ESA) ther …
HbA1c is the most accepted laboratory parameter for the long term observation of glucose control. There is still much of a debate abo …
Sequential therapy with cyclophosphamide and mycophenolic acid in patients with progressive immunoglobulin A nephropathy: a long-term follow-up.
Rasche FM, Keller F, Rasche WG, Schiekofer S, Kahn T, Fahnert J. Rasche FM, et al. Clin Exp Immunol. 2016 Feb;183(2):307-16. doi: 10.1111/cei.12719. Epub 2015 Nov 26. Clin Exp Immunol. 2016. PMID: 26439797 Free PMC article.
In progressive immunoglobulin (Ig)A nephropathy (IgAN), cyclophosphamide pulse therapy (CyP), high-dose intravenous immunoglobulins (IVIg) and mycophenolic acid (MPA) have been used to stop progressive loss of renal function, but disease progression may occur after the end of the …
In progressive immunoglobulin (Ig)A nephropathy (IgAN), cyclophosphamide pulse therapy (CyP), high-dose intravenous immunoglobulins (IVIg) a …
High-dose intravenous immunoglobulin pulse therapy in patients with progressive immunoglobulin A nephropathy: a long-term follow-up.
Rasche FM, Keller F, Lepper PM, Aymanns C, Karges W, Sailer LC, Müller Lv, Czock D. Rasche FM, et al. Clin Exp Immunol. 2006 Oct;146(1):47-53. doi: 10.1111/j.1365-2249.2006.03189.x. Clin Exp Immunol. 2006. PMID: 16968397 Free PMC article. Clinical Trial.
In progressive immunoglobulin A nephropathy (IgAN), intravenous immunoglobulin (IVIg) treatment has been used to delay disease progression, but the long-term efficacy is largely unknown. We report the clinical outcomes after IVIg therapy in six male patients with progressi …
In progressive immunoglobulin A nephropathy (IgAN), intravenous immunoglobulin (IVIg) treatment has been used to delay disease progression, …
Tonsillectomy, high dose immunoglobulins, and cyclophosphamide in progressive IgA-nephropathy.
Rasche FM, Sailer LC, Czock D, Keller F. Rasche FM, et al. Acta Otolaryngol Suppl. 2004 Dec;(555):32-7. doi: 10.1080/03655230410003305. Acta Otolaryngol Suppl. 2004. PMID: 15768795
Proteinuria significantly decreased only in patients after CyP from 1.3 g/l to 1.1 g/l. IVIG had no maintained long term effect on renal function, and TE/CTX had no significant influence on renal function. ...In conclusion, TE/CTX is not recommended in patients with advanc …
Proteinuria significantly decreased only in patients after CyP from 1.3 g/l to 1.1 g/l. IVIG had no maintained long term effect on re …
Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus.
Czock D, Aisenpreis U, Rasche FM, Jehle PM. Czock D, et al. Among authors: rasche fm. Int J Clin Pharmacol Ther. 2003 Oct;41(10):492-7. doi: 10.5414/cpp41492. Int J Clin Pharmacol Ther. 2003. PMID: 14703957 Clinical Trial.
PATIENTS AND METHODS: Eight patients with diabetes mellitus on long-term hemodialysis received an individualized dose of regular insulin or lispro-insulin in a crossover design. ...
PATIENTS AND METHODS: Eight patients with diabetes mellitus on long-term hemodialysis received an individualized dose of regular insu …
Pharmacokinetics of valganciclovir and ganciclovir in renal impairment.
Czock D, Scholle C, Rasche FM, Schaarschmidt D, Keller F. Czock D, et al. Among authors: rasche fm. Clin Pharmacol Ther. 2002 Aug;72(2):142-50. doi: 10.1067/mcp.2002.126306. Clin Pharmacol Ther. 2002. PMID: 12189361 Clinical Trial.
METHODS: A total of 44 patients were included-18 with mild, medium, or severe renal impairment; 6 with end-stage renal disease who were on long-term hemodialysis; 8 HIV/CMV-positive patients with normal renal function; and 12 healthy subjects serving as controls. ...
METHODS: A total of 44 patients were included-18 with mild, medium, or severe renal impairment; 6 with end-stage renal disease who were on l …